USFDA23 Oct 2026, 09:03 am
Cipla Subsidiary USFDA Inspection Concludes with Zero Observations
AI Summary
Cipla Ltd announced that its wholly owned subsidiary, InvaGen Pharmaceuticals Inc., located in Hauppauge, New York, underwent a routine current Good Manufacturing Practices (cGMP) inspection by the United States Food and Drug Administration (USFDA). The inspection, which took place from October 19th to October 22nd, 2026, concluded without any Form 483 observations. This outcome is positive for the subsidiary's operations and Cipla's overall compliance standing with US regulatory authorities.
Key Highlights
- USFDA inspection conducted at Cipla subsidiary InvaGen Pharmaceuticals.
- Inspection was a routine cGMP audit.
- The inspection concluded with zero Form 483 observations.
- Positive outcome for subsidiary's operational compliance.
Price Impact
More from CIPLA